Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dianthus Therapeutics, Inc. (DNTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company listed on The Nasdaq Capital Market under the symbol DNTH, Dianthus uses SEC reports to communicate material events, financial results, and key agreements related to its development of therapies for severe autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results, positive top-line Phase 2 data for claseprubart (DNTH103) in generalized myasthenia gravis, and an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants. Other 8-K filings describe a license and collaboration agreement with Nanjing Leads Biolabs Co. Ltd. for DNTH212 (LBL-047), outlining the exclusive license outside Greater China, milestone and royalty structure, and joint governance for development and commercialization.
Through this page, users can review how Dianthus reports its cash position, research and development expenses, and other financial metrics in connection with clinical-stage operations. Filings also document regulatory and corporate milestones that affect the company’s pipeline of investigational agents, including claseprubart and DNTH212, both of which are described as not approved as therapies in any indication in any jurisdiction worldwide.
Stock Titan enhances access to these filings with AI-powered summaries that explain the main points of lengthy documents, helping readers quickly understand material agreements, capital raises, and clinical or financial updates. Investors and researchers can use this resource to follow DNTH’s official disclosures, track changes over time, and connect specific filings to press releases and clinical news about the company’s autoimmune-focused programs.
Dianthus Therapeutics CEO and President Marino Garcia reported a stock option grant. On February 3, 2026, he was awarded a Stock Option (Right to Buy) covering 355,000 shares of common stock at an exercise price of $52.46 per share.
The option was granted at no cost as a derivative security and is held directly. The underlying 355,000 shares will vest in equal monthly installments over four years after January 1, 2026, contingent on his continued service with Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. is registering up to $600,000,000 of securities that it may offer over time. The shelf registration covers common stock, preferred stock, debt securities, warrants and units, which can be issued in one or more offerings with terms set in future prospectus supplements.
Dianthus is a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, led by its monoclonal antibody candidate claseprubart, designed to target the active form of the C1s complement protein. The company’s common stock trades on The Nasdaq Capital Market under the symbol “DNTH,” and the last reported sale price on January 27, 2026 was $50.31 per share.
The company expects to use net proceeds from any future sales primarily to fund preclinical and clinical development, working capital and general corporate purposes, and potentially to license, acquire or invest in additional product candidates.
Dianthus Therapeutics, Inc. filed a current report describing preliminary year-end liquidity. The company’s audited financial statements for the year ended December 31, 2025 are not yet available, but it expects to report approximately $514 million in cash, cash equivalents, and short-term investments as of December 31, 2025. This estimate is preliminary, unaudited, and subject to completion of year-end closing procedures, so actual results may differ materially.
The cash information is being shared in an investor presentation furnished as an exhibit, which will be used in meetings beginning January 12, 2026. The same presentation will also be used when President and CEO Marino Garcia speaks at the 44th Annual J.P. Morgan Healthcare Conference. The company notes that the presentation includes forward-looking statements and provides related cautionary language.
Dianthus Therapeutics (DNTH) reported Q3 2025 results. Revenue was $396 thousand from licensing. Research and development expense rose to $32.5 million and general and administrative expense was $8.2 million, driving a net loss of $36.8 million, or $0.97 per share.
The balance sheet strengthened following a September underwritten offering. Cash and cash equivalents were $55.984 million, with short‑term investments of $346.629 million and long‑term investments of $152.874 million. Total assets reached $577.4 million against total liabilities of $31.0 million, resulting in stockholders’ equity of $546.5 million.
In September, the company sold 7,627,879 shares at $33.00 and issued pre‑funded warrants for 1,112,121 shares at $32.999, for gross proceeds of $288.4 million, to fund development, working capital and general corporate purposes. The ATM program remains available with $160.8 million of capacity. Shares outstanding were 42,876,015 as of November 3, 2025. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financials’ issuance date.
Dianthus Therapeutics filed an 8-K stating it furnished a press release with financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed under Section 18, nor incorporated by reference except if specifically referenced.
Dianthus Therapeutics (DNTH) filed an 8-K to announce it has posted an updated corporate presentation on its investor relations website. The presentation is furnished as Exhibit 99.1 and is incorporated by reference.
The company notes the presentation contains forward-looking statements and includes cautionary language directing readers to related risk considerations. This is an informational update and does not disclose transaction terms or financial results.
Dianthus Therapeutics entered a License and Collaboration Agreement with Nanjing Leads Biolabs, securing exclusive rights outside Greater China to develop and commercialize DNTH212 (LBL-047), an investigational bifunctional fusion protein that targets pDC BDCA2 to reduce Type 1 interferon while inhibiting BAFF/APRIL to suppress B-cell function.
Consideration includes up to $38 million, comprised of $30 million in upfront and near‑term milestone payments and an additional $8 million milestone payable at the initiation of a Dianthus‑led Phase 1 study, at the company’s election in cash or stock. Leads may earn up to $962 million in development, regulatory, and sales milestones across five indications, plus tiered royalties from mid‑single digits up to low double‑digit on ex‑Greater China net sales.
A joint steering committee will oversee DNTH212; Leads can participate in global studies and enroll patients in Greater China and will cover certain related costs. The parties agreed to non‑competition outside Greater China. Dianthus reported approximately $555 million in cash, cash equivalents, and investments as of September 30, 2025, and $525 million pro forma after deducting near‑term and upfront payments.
Marino Garcia, who serves as CEO and President and a director of Dianthus Therapeutics, Inc. (DNTH), was awarded a stock option on 09/30/2025 to purchase 120,000 shares of the company's common stock at an exercise price of $39.35 per share. The option is exercisable through 09/30/2035 and will vest in equal monthly installments over the four years following the grant, subject to the reporting person’s continued service. After the grant the reporting person beneficially owns 120,000 shares underlying the option on a direct basis.
Ryan Savitz, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc. (DNTH), was granted a stock option on September 23, 2025 to purchase 60,000 shares of common stock at an exercise price of $37.87 per share. The option vests in equal monthly installments over four years beginning on the grant date and expires on September 23, 2035. The reporting on Form 4 was signed by an attorney-in-fact on September 25, 2025. The award is reported as a direct beneficial ownership of 60,000 underlying shares immediately following the transaction.